Join
Live feed
·
INSIDERFilingvia Quantisnow
Aardvark Therapeutics Inc. logo

Large owner Decheng Capital Global Life Sciences Fund Iv, L.P. converted options into 2,667,299 shares and bought $20,000,000 worth of shares (1,250,000 units at $16.00) (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AARD· Aardvark Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AARD (Aardvark Therapeutics Inc.) and more on Quantisnow.

Large owner Decheng Capital Global Life Sciences Fund Iv, L.P. converted options into 2,667,299 shares and bought $20,000,000 worth of shares (1,250,000 units at $16.00) (SEC Form 4) | Quantisnow